Prelude Therapeutics Inc Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -139.71M
Share-based Compensation 0.85M5.58M20.93M25.14M25.62M21.34M
Gains from Sales and Divestitures 0.04M
Gains from Investment Securities 0.38M-0.01M-0.71M1.80M1.92M14.21M
Non-cash Items 8.52M
Cash from Operations -25.66M-46.18M-83.53M-83.73M-107.06M-102.89M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles -1.36M-2.59M3.47M4.64M
Depreciation & Amortization (CF) 0.38M0.54M0.92M1.32M1.17M1.77M
Change in Working Capital
Change in Account Payables 0.55M1.16M3.90M-0.35M-2.27M3.31M
Change in Accured Expenses 1.47M4.61M2.46M6.83M2.52M-0.81M
Other Working Capital Changes 1.34M1.16M1.38M3.84M1.62M-1.05M
Investing Activities
Capital Expenditures 0.78M0.77M2.32M3.02M3.51M0.76M
Change in Acquisitions & Divestments 203.93M190.50M143.65M
Cash from Investing Activities -0.78M-0.62M-263.80M81.69M-34.65M90.19M
Financing Activities
Other financing activities 0.85M5.58M20.93M25.14M25.62M21.34M
Cash from Financing Activities 29.73M246.23M164.90M0.81M136.40M-0.12M
Additional items
Change in Cash 3.28M199.43M-182.44M-1.22M-5.31M-12.82M
Beginning Cash Balance -3.28M-199.43M182.44M1.22M5.31M29.34M
Free Cash Flow -26.45M-46.94M-85.85M-86.75M-110.58M-103.65M
Net Cash Flow 3.28M199.43M-182.44M-1.22M-5.31M-12.82M